NASDAQ:LGND • US53220K5048
Overall LGND gets a fundamental rating of 5 out of 10. We evaluated LGND against 192 industry peers in the Pharmaceuticals industry. While LGND has a great profitability rating, there are some minor concerns on its financial health. LGND has a correct valuation and a medium growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROIC | 1.58% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Altman-Z | 5.82 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.67 | ||
| Fwd PE | 23.44 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 126.88 | ||
| EV/EBITDA | 50.11 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
198.31
+2.14 (+1.09%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.67 | ||
| Fwd PE | 23.44 | ||
| P/S | 15.53 | ||
| P/FCF | 126.88 | ||
| P/OCF | 122.29 | ||
| P/B | 4.11 | ||
| P/tB | 9.55 | ||
| EV/EBITDA | 50.11 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROCE | 1.99% | ||
| ROIC | 1.58% | ||
| ROICexc | 2.92% | ||
| ROICexgc | 9.48% | ||
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% | ||
| FCFM | 12.24% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 3.38% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 96.15 | ||
| Cash Conversion | 50.63% | ||
| Profit Quality | 63.32% | ||
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 | ||
| Altman-Z | 5.82 |
ChartMill assigns a fundamental rating of 5 / 10 to LGND.
ChartMill assigns a valuation rating of 4 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.
The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.